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VALORISATION
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“Who would believe that so small a space could 
contain the images of all the universe?”
LEONARDO DA VINCI
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Of all the fields of Medicine, advances in technology have impacted Ophthalmology 
most. The world of retinal diseases is no exception. Vitreoretinal diseases that would 
have been deemed ‘inoperable’ a few years ago are routinely being done; retinal diseases 
that never would have been diagnosed, let alone treatable- are being diagnosed with 
Spectral domain optical coherence tomography (SD-OCT), OCT-Angiography, adaptive 
optics, microperimetry and treated- with the advent of micro incision vitrectomy surgery 
for example advanced diabetic tractional retinal detachments, stage 5 retinopathy of 
prematurity and complex traumas
Genetic diseases of the retina continue to frustrate clinicians (and patients) alike, as 
they are not amenable to conventional medical or surgical treatment. There is a ray of 
hope however tenuous at the present time, with the recent approval of gene therapy 
for RPE-65 related retinal dystrophies, and despite the multiple clinical trials ongoing 
around the world, the world is still a dark place for patients with these diseases. 
As I sat in the outpatient of the retina clinic many years ago, I saw this consanguineous 
couple with a young child, who had progressive visual failure and seizures. Over 
the next few weeks, as we informed the mother of the diagnosis of Batten’s disease 
(Neuronal ceroid Lipofuscinosis) in her child, the mother had a question: This was her 
fourth child; she now had three of her four children affected with this blinding and fatal 
condition. Why hadn’t any doctor told her about this before? Could we have prevented 
this condition in her children? In chapter 8 the basis for this opportunity to diagnose 
Neuronal ceroid Lipofuscinosis based on exome sequencing is described. 
This opened up the world of ‘retinal dystrophies’ and ‘ophthalmic genetics’ to me.  As I 
got more interested, I began to see more and more patients with degenerative diseases 
of the retina. 
My journey into the fascinating world of retinal dystrophies had begun. I knew this was 
an area of research that I wanted to pursue. 
Retinitis pigmentosa is the commonest retinal dystrophy. The prevalence of RP in India 
is more than 1 in 1000, compared to that of 1 in 4000 in the USA. That puts the number 
at close to 1.5 million affected with RP alone in India. This is not even considering other 
retinal dystrophies like Stargardt disease or LCA. Based on the prevalence alone this was 
then a socially relevant problem to study. Moreover, it supports the need to study this 
genetic disease from an Indian perspective and also find specific genetic mutations/
modifier genes fueled also by a high prevalence of consanguinity. 
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Was my study economically relevant? Undoubtedly. While there are several programs 
like the National Program for Control of Blindness, “orphan” diseases like retinal 
dystrophies receive very little attention. For every person who is blind, there are three 
people who are visually impaired. The economic burden of blindness in India for the 
year 1997 was Rs.159 billion (US$ 4.4 billion).  While 23.5 % of the blind in the world live 
in India, there are no definite statistics about blindness/visual impairment due to retinal 
degenerative diseases. 1,2
As I grappled to understand these diseases better, recent technological advances helped 
me get a better understanding of them. Looking at cone photoreceptors through 
Adaptive optics or getting better understanding of the blood flow in RP through 
Oximetry opened up newer insights into the pathogenesis of these diseases as described 
in Chapters 3 to 6. It now is possible to see the photoreceptors in vivo and study its density 
in RP. OCT also gave the opportunity to study the retina in much more detail in vivo in 
a detail almost similar to that achieved by histological examinations. Moreover, we are 
now better informed about the relation between the structural changes in Adaptive 
optics and OCT the function. The latter improved by micro-perimetry as compared to 
traditional perimetry. Microperimetry shows the sensitivity at a local point and at more 
points in the center and the opportunity to assess the sensitivity value in exactly the 
same place after some follow-up time. The sensitivity can therefore be closely related to 
the local changes in OA and OCT in the same spot.
As disease progression occurs in retinal dystrophies, the retinal tissue reacts to the 
injury in several ways; one of them is the formation of outer retinal tubules (ORT) 
described on the SD-OCT. I was curious to see how these tubules appeared on the 
adaptive optics; whether we could image them at all. Doing simple mathematical 
calculations based on the location of the ORTs on the SD-OCT, we identified possible 
locations of the tubules on the Adaptive optics; it was an exciting moment to see long 
tubules on stitched images of Adaptive Optics as is described in Chapter 4. It had not 
yet been described in Bietti’s Crystalline Dystrophy.
As we started conducting molecular genetic tests on the families presenting at our 
hospital, it became increasingly clear that there was limited information in the Indian 
literature regarding retinal dystrophies. While ophthalmic research is at the forefront in 
India, insights into the molecular genetics of retinal dystrophies was lacking. Towards 
this end, we published a series of mutations, both already noted and some new to add 
to the world literature (Chapters 7-9). Managing the staggering number of patients in 
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the genetic clinic brought fore the difficulties associated. (Chapter 10) Although we now 
had clinicians trained in managing patients with IRDs, there were no trained genetic 
counselors. Managing these patients and their families amidst a busy retina clinic was a 
challenge in itself. There were very few laboratories that were doing genetic mutational 
work in IRDs. Talking to multiple labs, discussing with them the importance of starting 
to look at eye/retina related genes, correlating them to the clinical phenotype- all 
taught me invaluable lessons. 
At Narayana Nethralaya, we hosted a two-day international symposium titled ‘SIGN- 
Symposium on Inherited Retinal Disease, Genetics and Newer treatments in 2013. This 
was a combination of presentations in basic genetics and clinical discussions. We were 
fortunate to have world leaders in the field of Ophthalmic Genetics come and address 
the sessions. And I continued to learn!
There is a surge in research into retinal dystrophies in the last decade. This thesis adds 
significantly to the existing literature about retinal dystrophies in India. With the many 
elements of research – be it gene therapy, stem cell research, retinal prostheses, small 
molecules, pharmaceutical therapy- we need more data about the spectrum of retinal 
dystrophies in India and its impact on the affected people. Once more data is gathered 
on the clinical phenotype, the number of affected people, the specific genetic mutations 
in the Indian population- it is then possible to start focusing on the therapies possible. 
Clinical trials in IRDs can then be started in India to look at multiple treatment options. 
Retinal prostheses- both epiretinal and subretinal have been approved for use today.3 
The USFDA approval of Luxturna- voretigene neparvovec-rzyl for RPE-65 disease 
developed by Spark therapeutics, USA is a very exciting landmark in the treatment of 
retinal dystrophies. However, gene therapy poses a very expensive prospect for affected 
patients. Each injection of Luxturna costs over $450,000 per injection currently in the 
United States. Although no patient in India has received either of these treatments yet, 
the development of both retinal prosthesis and gene therapy product is a remarkable 
achievement for science. In addition, both these therapies can behave like platform 
technologies based on which further products can be developed. 
There are several ophthalmic institutions in India doing research in this area - RP Centre 
for Ophthalmic Sciences, New Delhi, LV Prasad Eye Institute, Hyderabad, Sankara 
Nethralaya, Chennai, Aravind Eye Hospitals, Madurai, Narayana Nethralaya, Bangalore. 
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My own research has grown beyond the scope of this thesis. The Centre for Eye Genetics 
and Research in Bangalore (www.cegr.org) has been established with the sole idea of 
managing patients with retinal dystrophies, and provide the time and professional 
care these patients deserve. Services provided at CEGR include comprehensive clinical 
examination to arrive at a correct phenotype, genetic counseling after molecular 
genetic testing, clinical genetic services, personalized low visual rehabilitation services 
and collaboration with other organizations like ORDI (Organization for Rare Diseases 
India). Along with ORDI, CEGR has been organizing ‘Racefor7’, an annual marathon to 
raise awareness about rare diseases of the eye. 
What began as a small idea about exclusive management of these patients turned 
out to be the beginning of ‘Eyestem’ (www.eyestem.com). Eyestem is a retinal stem cell 
company that focuses on research into retinal degenerative diseases. It is incubated at 
CCamp (Centre for Cellular and molecular platforms), within the NCBS (National Centre 
for Biological Sciences) campus, Bangalore, India. Eyestem boasts of a dedicated set of 
scientists and an exceptional advisory team. 
The goal of the company is to be able to replace defective photoreceptors and 
retinal pigment epithelium in patients with retinal degenerative diseases. Towards 
this, we have used induced pluripotent stem cells (iPSC) from peripheral blood and 
differentiated them into Retinal Pigment Epithelium (RPE) and photoreceptors (PR) 
invitro.4 Our first set of animal experiments in dedicated knock out models has begun 
and we have shown successful integration of RPE cells transplanted subretinally.
Autologous stem cell treatment is possible; however the cell lines naturally carry the 
same genetic mutation that is in the eye. The combination of iPSC and remarkable 
genome editing tools like CRSIPR/Cas-9 (Clustered Regularly Interspaced Short 
Palindromic Repeats) make personalized therapy a reality, where a patient’s own cells 
are corrected and used to replace their degenerating retina.5 However this is bound to 
be a challenging and expensive proposition. 
Allogeneic stem cell treatment seems an attractive option to autologous treatment. 
Although the eye is considered immune-privileged, immune responses is one of 
the major hurdles for allogenic therapy. Systemic and local immunosuppression is 
administered in current trials; this research is still in its early stages. HLA matched 
allogeneic stem cell banks that are able to produce clinical grade cells seems a 
definite possibility. 
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At Eyestem, we are aware of challenges ahead. Some of these include overcoming 
immune responses, difficulties associated with integration of our cells within the host 
retina, clinical challenges of identifying critical end points in the disease and subretinal 
administration of the cells and associated regulatory hurdles. However, as science 
stands at the cusp of major breakthroughs in all these areas across the world, we are 
quite hopeful that we should be able to bring our current research to the bedside and 
be able to treat the many affected patients. 
To quote the famous French mathematician François Arago
 “To get to know, to discover, to publish- this is the destiny of a scientist”
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